Tilray Brands, Inc. (TLRY) Stock Forecast Nov. 6, 2026
Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Tilray Brands, Inc. (TLRY) stock forecast summary
Our AI scores Tilray Brands, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Tilray Brands, Inc. is a small-cap company with a market capitalization of $432M. It ranks number 4 by market capitalization among the 28 Medicinal Chemicals & Botanical Products issuers in our coverage with a current forecast.
For TLRY, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 12.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -1.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, TLRY included.
TLRY price chart and AI forecast
How TLRY ranks among 5150 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Tilray Brands, Inc. (TLRY) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Medicinal Chemicals & Botanical Products peers listed below that report each metric.
Valuation & Market
| Metric | TLRY | Rank |
|---|---|---|
| Market Cap | $432M | 4/28 |
| P/B Ratio | 0.27x | 12/13 |
| EPS | $-1.41 | – |
| Book Value/Share | $10.98 | – |
| Revenue/Share | $6.52 | – |
Profitability & Margins
| Metric | TLRY | Rank |
|---|---|---|
| ROE | -10.1% | 5/15 |
| ROA | -7.0% | 6/21 |
| ROIC | -4.7% | 10/18 |
| Gross Margin | 29.1% | 17/21 |
| Operating Margin | -9.3% | 11/23 |
| Net Margin | -17.1% | 10/19 |
| EBT Margin | -13.0% | 12/23 |
| Tax Rate | -16.8% | – |
Financial Health
| Metric | TLRY | Rank |
|---|---|---|
| Current Ratio | 1.88x | 9/25 |
| Quick Ratio | 1.11x | 8/23 |
| D/E Ratio | 0.44x | 11/16 |
| Financial Leverage | 1.43x | 11/16 |
| Interest Coverage | -0.6x | 11/21 |
| Working Capital | $377M | 4/25 |
Cash Flow
| Metric | TLRY | Rank |
|---|---|---|
| Operating Cash Flow | -$84M | 25/27 |
Operational Efficiency
| Metric | TLRY | Rank |
|---|---|---|
| Asset Turnover | 0.41x | 13/15 |
| Receivables Turnover | 5.0x | 14/14 |
| Inventory Turnover | 2.1x | 17/19 |
| Fixed Assets Turnover | 1.4x | 15/16 |
| Days Sales Outstanding | 72 days | 1/14 |
| Days Inventory | 176 days | 2/18 |
| Payables Period | 71 days | 4/17 |
| Cash Conversion Cycle | 177 days | 1/12 |
Income Statement
| Metric | TLRY | Rank |
|---|---|---|
| Total Revenue | $963M | 3/17 |
| Operating Income | -$89M | 21/26 |
| Net Income | -$164M | 17/21 |
| R&D Expense | $410K | 7/8 |
| SG&A Expense | $270M | 3/16 |
| Cost of Goods Sold | $683M | 1/22 |
Dividend & Shareholder Information
| Metric | TLRY | Rank |
|---|---|---|
| Shares Outstanding | 148M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $808M | 34.7% of assets |
| Cash & Short-term Investments | $215M | 9.2% of assets |
| Accounts Receivable | $191M | 8.2% of assets |
| Inventory | $329M | 14.1% of assets |
| Total Liabilities | $721M | 31.0% of assets |
| Short-term Debt | $297M | 12.8% of assets |
TLRY quarterly financials and insider trading
Tilray Brands, Inc. (TLRY) industry peers
Companies classified under the same SEC industry code as Tilray Brands, Inc. (Medicinal Chemicals & Botanical Products): 30 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| TLRY Tilray Brands, Inc. | $432M | |
| DFTX Definium Therapeutics, Inc. | $4.47B | |
| TRLV Trulieve Cannabis Corp. | $1.97B | |
| CRON Cronos Group Inc. | $1.33B | |
| SNDL Sndl Inc. | $355M | |
| ACB Aurora Cannabis Inc | $296M | |
| CGC Canopy Growth Corp | $276M | |
| USNA Usana Health Sciences Inc | $256M | |
| GLAS Glass House Brands Inc. | $196M | |
| MDWD Mediwound Ltd. | $171M | |
| NAGE Niagen Bioscience, Inc. | $164M | |
| AAWH Ascend Wellness Holdings, Inc. | $75M | |
| FTLF Fitlife Brands, Inc. | $75M | |
| CHUC Charlie's Holdings, Inc. | $31M | |
| BTMD Biote Corp. | $30M | |
| MRMD Marimed Inc. | $26M | |
| HYEX Healthy Extracts Inc. | $21M | |
| MTEX Mannatech Inc | $16M | |
| ADIA Adia Med, Inc. | $9M | |
| GLUC Glucose Health, Inc. | $9M | |
| BON Bon Natural Life Ltd | $7M | |
| NAII Natural Alternatives International Inc | $7M | |
| PLSH Panacea Life Sciences Holdings, Inc. | $6M | |
| AIBT Aibotics, Inc. | $3M | |
| CYAN Cyanotech Corp | $3M | |
| IMCC Im Cannabis Corp. | $980K | |
| NPHC Nutra Pharma Corp | $720K | |
| MEHA Functional Brands Inc. | $140K | |
| NTRR Neutra Corp. | N/A | |
| SNYRQ Synergy Chc Corp. | N/A |
Where TLRY sits on the market map
Tilray Brands, Inc. (TLRY) stock news
Loading...
Tilray Brands, Inc. (TLRY) stock forecast FAQ
What is the Tilray Brands, Inc. (TLRY) stock forecast?
Our AI scores Tilray Brands, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Tilray Brands, Inc. stock predictions?
For TLRY, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 12.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -1.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Tilray Brands, Inc. forecasts updated?
Tilray Brands, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Which companies are Tilray Brands, Inc.'s industry peers?
30 issuers in our coverage, TLRY included, share the SEC industry code Medicinal Chemicals & Botanical Products. The largest are: Definium Therapeutics, Inc. (DFTX), Trulieve Cannabis Corp. (TRLV), Cronos Group Inc. (CRON), Sndl Inc. (SNDL), Aurora Cannabis Inc (ACB), Canopy Growth Corp (CGC).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.